http://news.psu.edu/story/497450/2018/0 ... ients-live
Does anyone (or their onc) have a view on this recent Penn State study? The summary is that in a retrospective analysis of patients on immunotherapy, those that were also on pan beta-blockers showed much higher survival rates (70% 5-year survival) than those not on beta-blockers (25%). The focus was on melanoma patients, but given the parallels in treatment between that and CRC I think it's interesting for people who, like me, are on atezolizumab, pembro, nivo etc.
Best wishes to all,